Business
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Tasos Konidaris
About this update from Amneal Pharmaceuticals, Inc.
[{"type":"text","content":" BRIDGEWATER, N.J.--(BUSINESS WIRE)--\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr. Konidaris succeeds Todd Branning, who is no longer serving in this role, but remains available to the Company through March 31, 2020.\n\n\nMr. Konidaris brings to Amneal more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics and data industries. He most recently served as Chief Financial Officer and as a board member of Alcresta Therapeutics, Inc., a medical therapeutics company. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., a pharmaceutical company. Mr. Konidaris also previously served seven years as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation, as well as held various roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb.\n\n\nAmneal Co-Chief Executive Officers Chirag Patel and Chintu Patel said, “We are pleased to welcome Tasos as Amneal’s Chief Financial Officer. With his unique operations-focused perspective and deep cross-functional leadership experiences in the pharmaceutical industry, he is an excellent fit for Amneal. We are confident Tasos’s insights and expertise will further advance our ongoing efforts to unlock operating efficiencies and strategically deploy capital to reinvigorate the business. We look forward to working closely with him as we build on Amneal’s strong foundation to drive long-term growth and value for our stakeholders in 2020 and beyond.”\n\n\nMssrs. Patel continued, “We are grateful to Todd for his leadership and contributions to our Company, and we thank him for his work in helping Amneal navigate the challenging industry and market conditions we have experienced. We wish him all the best in his future endeavors.”\n\n\nMr. Konidaris said, “With its compelling diversification strategy, extensive portfolio of marketed commercial products and exciting pipeline of generics and specialty therapeutics products, I believe Amneal is building momentum and well-positioned for success. I am excited to work cl...